3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thromboembolism
1
Pulmonary Embolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
apixaban
4
abelacimab
2
MAA868
2
isoquercitrin
1
enoxaparin sodium
1
Rosuvastatin Calcium
1
Rivaroxaban
1
Heparin, Low-Molecular-Weight
1
Enoxaparin
1
Educational Status
1
Dalteparin
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pulmonary Embolism
×
isoquercitrin
×
1 year
×
Clear all
NCT06861088
2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3
Recruiting
480 enrolled